Saffron Supplementation in Stargardt's Disease (STARSAF02)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01278277 |
Recruitment Status : Unknown
Verified July 2017 by Benedetto Falsini, Catholic University of the Sacred Heart.
Recruitment status was: Active, not recruiting
First Posted : January 17, 2011
Last Update Posted : July 19, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Retinal Degeneration Genetic Disease Single-Gene Defects Macular Dystrophy | Dietary Supplement: Saffron supplementation Other: placebo | Phase 1 Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Novel Therapeutic Strategy Targeting Photoreceptor Oxidative Damage in ABCR-related Retinal Degenerations |
Study Start Date : | February 2011 |
Estimated Primary Completion Date : | November 2017 |
Estimated Study Completion Date : | December 2017 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: placebo supplementation
patients will be assigned, in a cross-over design, to placebo or supplement administration
|
Other: placebo
placebo supplementation |
Active Comparator: Saffron
Saffron Supplementation 20 mg/die
|
Dietary Supplement: Saffron supplementation
Saffron supplementation 20 mg
Other Name: Zaffit Special |
- Focal electroretinogram (FERG) [ Time Frame: six months ]ERGs will be elicited by the LED-generated sinusoidal luminance modulation of a circular uniform field (18° in diameter, 80 cd/m2 mean luminance, dominant wavelength: 630 nm), presented at the frequency of 41 Hz on the rear of a ganzfeld bowl, illuminated at the same mean luminance as the stimulus.
- Psychophysical recovery of cone system sensitivity after bleaching [ Time Frame: six months ]Psychophysical threshold will be determined at the paracentral visual field locations with preserved visual sensitivity, by presenting a 0.5 sec flashing light on a light adapting background of 20 cd/sqm. Following baseline assessment, the threshold intensity for the flashed light will be measured and plotted as a function of time, following 30 sec exposure to an adapting light (delivered in Maxwellian view by means of a calibrated indirect ophthalmoscope) whose intensity is estimated bleach approx 30% of the cone photopigment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 8 Years to 60 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Macular and peripheral retinal degeneration with typical funduscopic lesions (retinal flecks)
- Relatively preserved central retinal function
- Known genotype or genotype under study
Exclusion Criteria:
- absence of a rod-cone pattern of dysfunction
- acuity less than 0.1
- Unknown genotype

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01278277
Italy | |
Policlinico A. Gemelli | |
Rome, Italy, 00168 |
Principal Investigator: | Benedetto Falsini, MD | Catholic University of the Sacred Heart | |
Principal Investigator: | Marco Piccardi, MD | Catholic University of the Sacred Heart | |
Study Director: | Silvia Bisti, PhD | University of L'Aquila |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Benedetto Falsini, Associate Professor Ophthalmology, Catholic University of the Sacred Heart |
ClinicalTrials.gov Identifier: | NCT01278277 |
Other Study ID Numbers: |
STARSAF02 |
First Posted: | January 17, 2011 Key Record Dates |
Last Update Posted: | July 19, 2017 |
Last Verified: | July 2017 |
Stargardt disease macula electroretinogram saffron |
Retinal Degeneration Stargardt Disease Macular Degeneration Genetic Diseases, Inborn |
Eye Diseases, Hereditary Eye Diseases Retinal Diseases |